Park, K., Park, I., Lee, J. L. (2025). A randomized phase 3 trial of docetaxel added to ADT plus ARTA in patients with metastatic hormone-sensitive prostate cancer (Adding Docetaxel, KCSG- GU22-24).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.5_suppl.tps276